>Marché des tumeurs neuroendocrines en Asie-Pacifique, par classification (réseau fonctionnel et réseau non fonctionnel), site (poumon, pancréas, tractus gastro-intestinal (GI), grade (grade 1 {tumeur de bas grade}, grade 2 {tumeur de grade intermédiaire}, grade 3 {tumeur de haut grade}), type (diagnostic et traitement), voie d'administration (orale et parentérale), mode d'achat (sur ordonnance et en vente libre (OTC)), utilisateur final (hôpitaux, cliniques spécialisées, centres de radiothérapie, soins à domicile et autres), canal de distribution (appel d'offres direct, pharmacies hospitalières, pharmacies de détail, pharmacies en ligne et autres), pays (Chine, Japon, Inde, Australie, Corée du Sud, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Vietnam, reste de l'Asie-Pacifique) Tendances et prévisions de l'industrie jusqu'en 2028
Analyse et perspectives du marché : Marché des tumeurs neuroendocrines en Asie-Pacifique
Le marché des tumeurs neuroendocrines devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 11,5% au cours de la période de prévision de 2021 à 2028 et devrait atteindre 929,49 millions USD d'ici 2028. Les initiatives stratégiques des acteurs du marché et l'avènement des programmes de vaccination de masse pour les tumeurs neuroendocrines sont susceptibles d'être les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
L'initiation d'une tumeur se produit lorsque l'ADN des cellules saines est endommagé, ce qui entraîne une modification et une croissance incontrôlée des cellules, formant ainsi une masse agrégée de cellules. Une tumeur peut être cancéreuse et bénigne. Une tumeur cancéreuse maligne se développe et se propage à d'autres parties du corps si elle n'est pas détectée et traitée tôt. Une tumeur bénigne peut se développer mais ne se propage pas. Une tumeur bénigne peut généralement être retirée par chirurgie mini-invasive sans causer beaucoup de dommages. Une tumeur neuroendocrine (TNE) commence dans les cellules spécialisées du système neuroendocrinien du corps. Ces cellules ont des caractéristiques communes à la fois aux cellules endocrines productrices d'hormones et aux cellules nerveuses. Elles se trouvent dans tous les organes du corps et sont responsables du contrôle de nombreuses fonctions du corps. Toutes les TNE sont considérées comme des tumeurs malignes. La plupart des TNE mettent de nombreuses années à se développer et à croître lentement.
Cependant, des facteurs tels que les effets secondaires associés aux traitements, les besoins non satisfaits et l'accès aux ressources médicales dans plusieurs régions, le coût élevé du diagnostic freinent la croissance du marché des tumeurs neuroendocrines. D'autre part, les traitements ciblés à venir et l'augmentation des partenariats et collaborations entre les acteurs du marché constituent une opportunité pour la croissance du marché des tumeurs neuroendocrines. L'absence de politiques de remboursement et les réglementations gouvernementales strictes pour le développement de médicaments contre les tumeurs neuroendocrines sont les défis auxquels est confronté le marché des tumeurs neuroendocrines.
Le rapport sur le marché des tumeurs neuroendocrines fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, les changements dans la réglementation du marché, les approbations de produits, les décisions stratégiques, les lancements de produits, les expansions géographiques et les innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché des tumeurs neuroendocrines
Le marché des tumeurs neuroendocrines est segmenté en fonction de la classification, du site, du grade, du type, de la voie d'administration, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base de la classification , le marché des tumeurs neuroendocrines est segmenté en réseau fonctionnel et réseau non fonctionnel. En 2021, le segment du réseau non fonctionnel domine le marché des tumeurs neuroendocrines en raison de la facilité d'identification et de diagnostic et de l'utilisation d'une nouvelle méthode de diagnostic pour éliminer le réseau non fonctionnel.
- Sur la base du site, le marché des tumeurs neuroendocrines est segmenté en poumon , pancréas et tractus gastro-intestinal (GI). En 2021, le segment du tractus gastro-intestinal (GI) domine le marché des tumeurs neuroendocrines en raison de la prévalence accrue du cancer gastrique et de la présence d'un solide pipeline de produits qui devrait dominer le marché.
- Sur la base du grade, le marché des tumeurs neuroendocrines est segmenté en grade 1 (tumeur de bas grade), grade 2 (tumeur de grade intermédiaire) et grade 3 (tumeur de haut grade). En 2021, le segment de grade 2 (tumeur de grade intermédiaire) domine le marché des tumeurs neuroendocrines car il peut être facilement guéri par des traitements thérapeutiques et l'augmentation des cas de grade 2 (tumeur de grade intermédiaire) devrait dominer le marché.
- Sur la base du type, le marché des tumeurs neuroendocrines est segmenté en diagnostic et traitement. En 2021, le segment du diagnostic devrait dominer le marché des tumeurs neuroendocrines en raison de l'incidence accrue du cancer du pancréas et de l'adoption accrue du diagnostic automatisé au point de service sur le marché.
- En fonction de la voie d'administration, le marché des tumeurs neuroendocrines est segmenté en voie orale et parentérale. En 2021, le segment oral devrait dominer le marché des tumeurs neuroendocrines en raison de la disponibilité des médicaments sous forme orale, d'une meilleure observance du traitement par les patients et de la facilité d'absorption.
- On the basis of end user, the neuroendocrine tumors market is segmented into hospitals, specialty clinics, radiation centers, home healthcare and others. In 2021, hospitals segment is expected to dominate the neuroendocrine tumors market due to the availability of diagnostics machines to detect neuroendocrine tumor with the availability of healthcare policies.
- On the basis of distribution channel, the neuroendocrine tumors market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is expected to dominate the neuroendocrine tumors market due to rise of suppliers in the market.
Neuroendocrine Tumors Market Country Level Analysis
The neuroendocrine tumors market is analysed and market size information is provided classification, site, grade, type, route of administration, end user and distribution channel as referenced above.
The countries covered in the neuroendocrine tumors market report are China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific.
Asia-Pacific is expected to grow with the highest CAGR in the forecast period. China is expected to dominate in the market as the demand for neuroendocrine tumors product is increasing very rapidly with the urbanization and laboratory automation.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Government Initiatives and the Rising Collaborations by Market Players are creating new Opportunities in the Neuroendocrine Tumors Market
Neuroendocrine tumors market also provides you with detailed market analysis for every country growth in particular industry with neuroendocrine tumors sales, impact of advancement in the neuroendocrine tumors and changes in regulatory scenarios with their support for the neuroendocrine tumors market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Neuroendocrine Tumors Market Share Analysis
Le paysage concurrentiel du marché des tumeurs neuroendocrines fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise liée au marché des tumeurs neuroendocrines.
Les principales entreprises du marché des tumeurs neuroendocrines sont Novartis AG, Ipsen Pharma, Viatris Inc., Callisto Pharmaceuticals, Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline plc, Thermo Fisher Scientific Inc., Hutchison China MediTech Limited, F. Hoffmann-La Roche Ltd, Bionano Genomics, Teva Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., une filiale de Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Illumina, Inc. et LUPIN, entre autres acteurs mondiaux ou nationaux. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux lancements de produits et accords sont également initiés par les entreprises du monde entier, ce qui accélère également le marché des tumeurs neuroendocrines.
Par exemple,
- En janvier 2018 , Novartis AG a annoncé qu'Advanced Accelerator Applications, une filiale de Novartis AG, avait reçu l'approbation de la FDA pour sa nouvelle demande d'homologation du médicament Lutathera (lutetium Lu 177 dotatate*) pour le traitement des tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP) positives au récepteur de la somatostatine, notamment les tumeurs neuroendocrines de l'intestin antérieur, moyen et postérieur chez l'adulte. L'approbation de la FDA reçue par la société a entraîné une augmentation des essais cliniques, un portefeuille de produits oncologiques enrichi en neurologie et devrait générer une croissance positive du marché.
La collaboration, les coentreprises et d’autres stratégies des acteurs du marché améliorent le marché de l’entreprise sur le marché des tumeurs neuroendocrines, ce qui offre également l’avantage à l’organisation d’améliorer son offre de traitement.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASSIFICATION LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 PRICING ANALYSIS
7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: REGULATIONS
7.1 REGULATORY PROCEDURE IN THE U.S.
7.2 REGULATORY PROCEDURE IN CANADA
7.3 REGULATORY PROCEDURE IN EUROPE
7.4 REGULATORY PROCEDURE IN CHINA
7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA
8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY
8.1 MONOCLONAL ANTIBODY
8.2 POLYCLONAL ANTIBODY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES
9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS
9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS
9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS
9.1.5 FAVORABLE REIMBURSEMENT POLICIES
9.2 RESTRAINTS
9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS
9.2.2 LACK OF AWARENESS AMONG THE POPULATION
9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS
9.2.4 HIGH COST OF DIAGNOSIS
9.3 OPPORTUNITIES
9.3.1 INCREASED GOVERNMENT INITIATIVES
9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT
9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS
9.4 CHALLENGES
9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS
9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS
10 IMPACT OF COVID 19 ON ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET
10.1 PRICE IMPACT
10.2 IMPACT OF DEMAND
10.3 IMPACT ON SUPPLY CHAIN:
10.4 STRATEGIC DECISIONS:
10.5 CONCLUSION:
11 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION
11.1 OVERVIEW
11.2 NON-FUNCTIONAL NET
11.3 FUNTIONAL NET
12 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE
12.1 OVERVIEW
12.2 GASTROINTESTINAL TRACT (GI)
12.3 LUNGS
12.4 PANCREAS
13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE
13.1 OVERVIEW
13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR)
13.3 GRADE 3 (HIGH-GRADE TUMOR)
13.4 GRADE 1( LOW-GRADE TUMOR)
14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE
14.1 OVERVIEW
14.2 DIAGNOSIS
14.2.1 BLOOD TEST
14.2.2 IMAGING TEST
14.2.2.1 CTSCAN
14.2.2.2 MRI
14.2.2.3 OTHERS
14.2.3 BIOPSY
14.2.4 URINE TEST
14.2.5 OTHERS
14.3 TREATMENT
14.3.1 SOMATOSTATIN ANALOGS
14.3.1.1 OCTREOTIDE
14.3.1.2 LANREOTIDE
14.3.2 TARGETED THERAPY
14.3.2.1 EVEROLIMUS
14.3.2.2 SUNITINIB
14.3.2.3 OTHERS
14.3.3 RADIATION THERAPY
14.3.3.1 EXTERNAL-BEAM RADIATION
14.3.3.2 INTERNAL-BEAM RADIATION
14.3.4 SURGERY
14.3.4.1 CHOLECYSTECTOMY
14.3.4.2 OTHERS
14.3.5 LIVER-DIRECTED TREATMENT
14.3.5.1 RADIO FREQUENCY ABLATION (RFA)
14.3.5.2 HEPATIC ARTERY EMBOLIZATION
14.3.5.3 RADIOEMBOLIZATION
14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA
15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS
15.2.2 PILLS
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 SUBCUTANEOUS
15.3.2 INTRAMUSCULAR
15.3.3 OTHERS
16 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALITY CLINICS
16.4 RADIATION CENTERS
16.5 HOME HEALTHCARE
16.6 OTHERS
17 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL SALES
17.5 ONLINE PHARMACY
17.6 OTHERS
18 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY
18.1 ASIA PACIFIC
18.1.1 CHINA
18.1.2 JAPAN
18.1.3 INDIA
18.1.4 AUSTRALIA
18.1.5 MALAYSIA
18.1.6 INDONESIA
18.1.7 SOUTH KOREA
18.1.8 SINGAPORE
18.1.9 PHILIPPINESS
18.1.10 THAILAND
18.1.11 VIETNAM
18.1.12 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT
21 COMPANY PROFILES
21.1 F. HOFFMANN-LA ROCHE LTD
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 BRISTOL-MYERS SQUIBB COMPANY
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 VIATRIS INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 COMPANY SHARE ANALYSIS
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENTS
21.4 THERMO FISHER SCIENTIFIC INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 NOVARTIS AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 REGENERON PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 BIONANO GENOMICS
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 BIOSYNTHEMA INC.
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 CALLISTOPHARMA
21.10.1 COMPANY SNAPSHOT
21.10.2 PRODUCT PORTFOLIO
21.10.3 RECENT DEVELOPMENTS
21.11 ELI LILLY AND COMPANY
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENTS
21.12 EXACT SCIENCES CORPORATION
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 GLAXOSMITHKLINE PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 HUTCHISON CHINA MEDITECH LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 IPSEN PHARMA
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 ILLUMINA, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 LUPIN
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 PFIZER INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENTS
21.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Liste des tableaux
TABLE 1 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS
TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020
TABLE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION)
TABLE 4 ASIA-PACIFIC NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 5 ASIA-PACIFIC FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC LIVER-DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC HOSPITALS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC SPECIALITY CLINICS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC RADIATION CENTERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC OTHERS IN RADIOTHERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 ASIA-PACIFIC OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC DIRECT TENDER IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HOSPITAL PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC RETAIL SALES IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC ONLINE PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 44 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 45 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 46 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 47 ASIA PACIFICDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 48 ASIA PACIFICIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 49 ASIA PACIFICTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 50 ASIA PACIFICSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 51 ASIA PACIFICTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 52 ASIA PACIFICRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 ASIA PACIFICSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 54 ASIA PACIFICLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 55 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 56 ASIA PACIFICORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 57 ASIA PACIFICPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 58 ASIA PACIFICNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 59 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 60 CHINANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 61 CHINANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 62 CHINANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 63 CHINANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 64 CHINADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 65 CHINAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 66 CHINATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 67 CHINASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 68 CHINATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 69 CHINARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 CHINASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 71 CHINALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 72 CHINANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 73 CHINAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 74 CHINAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 75 CHINANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 76 CHINA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 77 JAPANNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 78 JAPANNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 79 JAPANNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 80 JAPANNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 JAPANDIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 82 JAPANIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 83 JAPANTREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 84 JAPANSOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 85 JAPANTARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 86 JAPANRADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 87 JAPANSURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 88 JAPANLIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 89 JAPANNEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 90 JAPANORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 91 JAPANPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 92 JAPANNEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 93 JAPAN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 94 INDIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 95 INDIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 96 INDIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 97 INDIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 98 INDIADIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 99 INDIAIMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 100 INDIATREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 101 INDIASOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 INDIATARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 103 INDIARADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 104 INDIASURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 105 INDIALIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 106 INDIANEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 107 INDIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 108 INDIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 109 INDIANEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 110 INDIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 111 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 112 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 113 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 114 AUSTRALIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 115 AUSTRALIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 116 AUSTRALIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 117 AUSTRALIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 118 AUSTRALIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 119 AUSTRALIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 AUSTRALIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 121 AUSTRALIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 122 AUSTRALIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 123 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 124 AUSTRALIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 125 AUSTRALIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 126 AUSTRALIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 127 AUSTRALIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 128 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 129 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 130 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 131 MALAYSIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 132 MALAYSIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 133 MALAYSIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 134 MALAYSIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 135 MALAYSIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 136 MALAYSIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 MALAYSIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 MALAYSIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 139 MALAYSIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 140 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 141 MALAYSIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 142 MALAYSIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 143 MALAYSIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 144 MALAYSIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 145 INDONESIANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 146 INDONESIANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 147 INDONESIANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 148 INDONESIANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 INDONESIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 150 INDONESIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 151 INDONESIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 152 INDONESIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 INDONESIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 154 INDONESIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 INDONESIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 INDONESIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 INDONESIAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 158 INDONESIAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 159 INDONESIAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 160 INDONESIAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 161 INDONESIA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 162 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 163 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 164 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 165 SOUTH KOREANEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 166 SOUTH KOREA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 167 SOUTH KOREA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 168 SOUTH KOREA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 169 SOUTH KOREA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 170 SOUTH KOREA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 171 SOUTH KOREA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 172 SOUTH KOREA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 173 SOUTH KOREA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 174 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 175 SOUTH KOREAORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 176 SOUTH KOREAPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 177 SOUTH KOREAEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 178 SOUTH KOREA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 179 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 180 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 181 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 182 SINGAPORENEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 183 SINGAPORE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 184 SINGAPORE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 185 SINGAPORE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 186 SINGAPORE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 187 SINGAPORE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 188 SINGAPORE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 189 SINGAPORE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 190 SINGAPORE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 191 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 192 SINGAPOREORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 193 SINGAPOREPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 194 SINGAPOREEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 195 SINGAPORE NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 196 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 197 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 198 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 199 PHILIPPINESSNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 200 PHILIPPINESS DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 201 PHILIPPINESS IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 202 PHILIPPINESS TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 203 PHILIPPINESS SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 204 PHILIPPINESS TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 205 PHILIPPINESS RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 206 PHILIPPINESS SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 207 PHILIPPINESS LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 208 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 209 PHILIPPINESSORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 210 PHILIPPINESSPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 211 PHILIPPINESSEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 212 PHILIPPINESS NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 213 THAILAND NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 214 THAILANDNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 215 THAILANDNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 216 THAILANDNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 217 THAILAND DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 218 THAILAND IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 219 THAILAND TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 220 THAILAND SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 221 THAILAND TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 222 THAILAND RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 223 THAILAND SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 224 THAILAND LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 225 THAILANDEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 226 THAILANDORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 227 THAILANDPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 228 THAILANDEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 229 THAILAND NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 230 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 231 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 232 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 233 VIETNAMNEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 234 VIETNAM DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 235 VIETNAM IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 236 VIETNAM TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 237 VIETNAM SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 238 VIETNAM TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 239 VIETNAM RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 240 VIETNAM SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 241 VIETNAM LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 242 VIETNAMEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 243 VIETNAMORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 244 VIETNAMPARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 245 VIETNAMEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 246 VIETNAM NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 247 REST OF ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
Liste des figures
FIGURE 1 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: ASIA-PACIFIC VS REGIONAL ANALYSIS
FIGURE 5 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 11 INCREASED AWARENESS OF NEUROENDOCRINE TUMORS CASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 NON-FUNTIONAL NET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET IN 2021 & 2028
FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016
FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S.
FIGURE 15 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, 2020
FIGURE 16 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2020-2028 (USD MILLION)
FIGURE 17 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, CAGR (2021-2028)
FIGURE 18 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, LIFELINE CURVE
FIGURE 19 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, 2020
FIGURE 20 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY SITE, 2020-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY SITE, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, 2020
FIGURE 24 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2020-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, CAGR (2021-2028)
FIGURE 26 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY GRADE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, 2020
FIGURE 28 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2020-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 30 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, 2020
FIGURE 36 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY END USER, 2020-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020)
FIGURE 44 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020)
FIGURE 45 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 ASIA PACIFIC NEUROENDOCRINE TUMORS MARKET: BY STRAINS (2021-2028)
FIGURE 48 ASIA-PACIFIC NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
